ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Clinical trial NCT06816992 · RECRUITING

Trial details

NCT number: NCT06816992
Sponsor: ORIC Pharmaceuticals
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors EGFR Exon 20 Insertion Mutations NSCLC EGFR-mutated NSCLC

Start date: 2025-02-27
Primary completion: 2026-12-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.